Literature DB >> 1083350

Symptomatic hepatic disease in cystic fibrosis: incidence, course, and outcome of portal systemic hunting.

R C Stern, D P Stevens, T F Boat, C F Doershuk, R J Izant, L W Matthews.   

Abstract

Fifteen (2.2%) of 693 patients with cystic fibrosis seen over an 18-year period developed clinical hepatic disease. In 13 patients all symptoms were secondary to portal hypertension. Ten had hypersplenism and 6 had variceal bleeding, including 3 who developed both conditions. All 5 patients who survived the initial episode of gastrointestinal bleeding underwent portal systemic shunting. A shunting procedure also was performed on 1 patients with hypersplenism but no variceal bleeding. No subsequent deterioration of intellectual function occurred in either the shunted or unshunted patients. Only 1 of the shunted patients showed progression of hepatic disease after surgery. These results suggest that portal systemic shunting is useful in the treatment of bleeding esophageal varices in cystic fibrosis. A sweat test to rule out cystic fibrosis should be included in the evaluation of any teenage or young adult patient with unexplained portal hypertension.

Entities:  

Mesh:

Year:  1976        PMID: 1083350

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  11 in total

1.  Prevalence of liver disease in cystic fibrosis.

Authors:  R Scott-Jupp; M Lama; M S Tanner
Journal:  Arch Dis Child       Date:  1991-06       Impact factor: 3.791

2.  Liver transplantation in cystic fibrosis.

Authors:  S P Revell; G Noble-Jamieson; N R Roberton; N D Barnes
Journal:  J R Soc Med       Date:  1993-02       Impact factor: 5.344

3.  Liver transplantation for hepatic cirrhosis in cystic fibrosis.

Authors:  G Noble-Jamieson; J Valente; N D Barnes; P J Friend; N V Jamieson; A Rasmussen; R Y Calne
Journal:  Arch Dis Child       Date:  1994-10       Impact factor: 3.791

4.  Effects of ursodeoxycholic acid treatment on nutrition and liver function in patients with cystic fibrosis and longstanding cholestasis.

Authors:  J Cotting; M J Lentze; J Reichen
Journal:  Gut       Date:  1990-08       Impact factor: 23.059

5.  False diagnosis of non-A/non-B hepatitis hiding two cases of cystic fibrosis.

Authors:  M Resti; C Adami Lami; F Tucci; F Mannelli; M E Rossi; C Azzari; A Vierucci
Journal:  Eur J Pediatr       Date:  1990-12       Impact factor: 3.183

6.  Serum hyaluronic acid concentrations are increased in cystic fibrosis patients with liver disease.

Authors:  H A Wyatt; A Dhawan; P Cheeseman; G Mieli-Vergani; J F Price
Journal:  Arch Dis Child       Date:  2002-03       Impact factor: 3.791

7.  An approach for treating the hepatobiliary disease of cystic fibrosis by somatic gene transfer.

Authors:  Y Yang; S E Raper; J A Cohn; J F Engelhardt; J M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

8.  Spontaneous bacterial peritonitis in cystic fibrosis.

Authors:  C F Doershuk; R C Stern
Journal:  Gut       Date:  1994-05       Impact factor: 23.059

Review 9.  Cystic fibrosis.

Authors:  M R Bye; J M Ewig; L M Quittell
Journal:  Lung       Date:  1994       Impact factor: 2.584

10.  Immune responses to liver membrane antigens in patients with cystic fibrosis and liver disease.

Authors:  G Mieli-Vergani; H T Psacharopoulos; A M Nicholson; A L Eddleston; A P Mowat; R Williams
Journal:  Arch Dis Child       Date:  1980-09       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.